A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Jennifer Gaines
- Phone Number: +1 (415) 295-4770
- Email: admin@iantechmed.com
Study Locations
-
-
-
Panama, Panama
- Recruiting
- Clinica de Ojos Panama City
-
Contact:
- Ernesto Calvo, MD
- Phone Number: (305) 898-0472
- Email: ecalvo86@mac.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to understand study requirements, willing to follow study instructions and willing to return for required study follow-up visits as confirmed by provision of written informed consent.
- Subjects with a visually significant cataract scheduled to undergo cataract surgery
- Subjects > 18 years of age
- BCVA at baseline not better than 20/40
- Grade 1+ cataracts
Exclusion Criteria:
- Subjects not able to complete the informed consent form
- Subjects < 18 years of age
- Polar cataracts
- Zonular instability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: LEEP Intervention C1
Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
|
Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
|
|
ACTIVE_COMPARATOR: LEEP Intervention C2
Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
|
Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
|
|
PLACEBO_COMPARATOR: Control Phaco C2
Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative Dispersed Phaco energy
Time Frame: Intraoperative
|
Total phaco power and energy used as recorded by the phaco machine
|
Intraoperative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endothelial cell loss
Time Frame: 1 month
|
Change from baseline endothelial cell density as measured by specular microscopy
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LEEP103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.